Last reviewed · How we verify
Deferiprone sustained-release — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Deferiprone sustained-release (Deferiprone sustained-release) — ApoPharma. Deferiprone chelates excess iron by binding to ferric ions, forming stable complexes that are excreted primarily in urine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Deferiprone sustained-release TARGET | Deferiprone sustained-release | ApoPharma | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Deferiprone sustained-release CI watch — RSS
- Deferiprone sustained-release CI watch — Atom
- Deferiprone sustained-release CI watch — JSON
- Deferiprone sustained-release alone — RSS
Cite this brief
Drug Landscape (2026). Deferiprone sustained-release — Competitive Intelligence Brief. https://druglandscape.com/ci/deferiprone-sustained-release. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing